Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.04% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Operating Margin
Axonics Inc

-1.7%
Current
-16%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.7%
=
Operating Profit
-7.2m
/
Revenue
431.9m

Operating Margin Across Competitors

Country US
Market Cap 3.6B USD
Operating Margin
-2%
Country US
Market Cap 204.9B USD
Operating Margin
17%
Country US
Market Cap 195.2B USD
Operating Margin
26%
Country US
Market Cap 146.7B USD
Operating Margin
22%
Country US
Market Cap 132.6B USD
Operating Margin
18%
Country IE
Market Cap 110.6B USD
Operating Margin
19%
Country US
Market Cap 64.7B USD
Operating Margin
14%
Country DE
Market Cap 55.6B EUR
Operating Margin
12%
Country CN
Market Cap 319.2B CNY
Operating Margin
37%
Country US
Market Cap 41.6B USD
Operating Margin
28%
Country US
Market Cap 37.7B USD
Operating Margin
13%
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.

AXNX Intrinsic Value
33.81 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.7%
=
Operating Profit
-7.2m
/
Revenue
431.9m
What is the Operating Margin of Axonics Inc?

Based on Axonics Inc's most recent financial statements, the company has Operating Margin of -1.7%.